2022
Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaseline
2018
Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries
Klingensmith GJ, Lanzinger S, Tamborlane WV, Hofer SE, Cheng P, de Beaufort C, Gal RL, Reinehr T, Kollman C, Holl RW. Adolescent type 2 diabetes: Comparing the Pediatric Diabetes Consortium and Germany/Austria/Luxemburg Pediatric Diabetes Prospective registries. Pediatric Diabetes 2018, 19: 1156-1163. PMID: 29923263, DOI: 10.1111/pedi.12712.Peer-Reviewed Original ResearchConceptsDiabetes durationClinical characteristicsBody mass index SDSAdolescent type 2Onset of T2DPediatric Diabetes ConsortiumShorter diabetes durationMost recent visitType 2 diabetesYears of ageProspective registryTreatment of youthAdverse eventsDiabetes complicationsHigher HbA1cOffice visitsHigher hemoglobinUnited States databaseVs 3.2Diabetes testingType 2RegistryLaboratory dataTreatment differencesFurther studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply